Emergent BioSolutions, Inc. (EBS)
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$6.21-0.32%
Close 2026-09-04 · 1-day change
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · EBS
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 9 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $6.21 EBS trades at 4.3× p/e, below its 16× p/e peer median. Our $20 fair value sits well above the price. We hold it with medium confidence: the peer anchor overstates how cheap it looks. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| dcf fcfe | 12M | $26.09 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $28.80 | — | — | Hist. CAGR | high |
| graham number | 12M | $14.64 | — | — | TTM | high |
| Peer P/FCF | 12M | $23.52 | 14.1 | 1.66 | TTM | high |
| Peer P/E | 12M |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Only weak execution quality — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks cheaper than most peers in the same business.
Cheaper than its own typical valuation.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
| $23.14 |
| 16.1 |
| 1.44 |
| TTM |
| high |
| Peer P/S | 12M | $42.93 | 2.9 | 14.78 | TTM | high |
| residual income | 12M | $10.08 | — | — | TTM | high |
| Own P/E history | 12M | $10.99 | 7.6 | 1.44 | TTM | high |
| triangulated | 12M | $25.45 | 16.1 | 1.58 | Triangulated | high |
| Peer P/E | 3Y | $34.92 | 16.1 | 2.17 | Hist. CAGR(prov.) | medium |
| Peer P/S | 3Y | $50.54 | 2.9 | 17.39 | guidance | medium |
| Own P/E history | 3Y | $16.58 | 7.6 | 2.17 | Hist. CAGR(prov.) | medium |
| Peer P/E | 5Y | $38.93 | 16.1 | 2.42 | Hist. CAGR(prov.) | medium |
| Peer P/S | 5Y | $56.34 | 2.9 | 19.39 | guidance | medium |
| Own P/E history | 5Y | $18.49 | 7.6 | 2.42 | Hist. CAGR(prov.) | medium |